MOSMDSVYwqgkTZI
I'm from England http://rubik3.com.au/womeninmedicinecouk-cddb.pdf medjourneys.com
UPDATE: In an investor note, Cowen & Co analyst Simos Simeonidis wrote that the move demonstrates Eisai’s further commitment to supporting the drug, adding that it will provide an incremental commercial advantage to Belviq that Vivus will have to deal with, and makes Vivus' need for a pharma partnership even greater". However, he added that "this change in the commercial marketplace does not change the drug's clinical profile, and this is where we believe Belviq is at a disadvantage".
Page:[1]